What's new? Log in Free sign up

Akero Therapeutics (AKRO)

Company Profile

Company profile

Ticker

AKRO

Exchange

Website

www.akerotx.com

CEO

Dr. Andrew Cheng M.D., Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

HIVE Blockchain Technologies Ltd.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Akero Securities Corporation ...

AKRO stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$84.20

Low target

$63.00

High target

$109.00

B of A Securities

Canaccord Genuity

Latest filings (excl ownership)

View all

Entry into a Material Definitive Agreement

Prospectus supplement for primary offering

Free writing prospectus

Prospectus supplement for primary offering

Results of Operations and Financial Condition

Quarterly report

8 Nov 24

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Quarterly report

9 Aug 24

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Amendments to Articles of Incorporation or Bylaws

Latest ownership filings

View all

G. Walmsley Graham

Financial summary

Financial statements Chart AKRO financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	316.07 mm	316.07 mm	316.07 mm	316.07 mm	316.07 mm	316.07 mm
Cash burn (monthly)	(no burn)	(no burn)	27.23 mm	22.44 mm	23.47 mm	17.64 mm
Cash used (since last report)	n/a	n/a	119.90 mm	98.79 mm	103.34 mm	77.64 mm
Cash remaining	n/a	n/a	196.17 mm	217.28 mm	212.72 mm	238.42 mm
Runway (months of cash)	n/a	n/a	7.2	9.7	9.1	13.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

AKRO institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	177	159	+11.3%
Opened positions	35	21	+66.7%
Closed positions	17	38	-55.3%
Increased positions	49	58	-15.5%
Reduced positions	57	52	+9.6%

13F shares	Current	Prev Q	Change
Total value	1.93 tn	1.54 tn	+25.5%
Total shares	82.02 mm	80.84 mm	+1.5%
Total puts	616.20 k	133.40 k	+361.9%
Total calls	238.80 k	175.80 k	+35.8%
Total put/call ratio	2.6	0.8	+240.1%

Largest owners	Shares	Value	Change
Wellington Management	7.90 mm	$226.55 bn	+54.4%
JHG Janus Henderson	7.08 mm	$203.05 bn	+2.9%
RTW Investments	5.92 mm	$169.83 bn	+9.0%
BlackRock	5.75 mm	$164.90 bn	NEW
General Atlantic	5.23 mm	$150.16 bn	0.0%
T. Rowe Price	3.81 mm	$109.26 mm	-8.2%
Vanguard	3.68 mm	$105.48 bn	-0.8%
Alkeon Capital Management	3.33 mm	$95.39 bn	-0.1%
venBio Global Strategic Fund	3.03 mm	$106.05 mm	0.0%
PFE Pfizer	2.53 mm	$56.41 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
BlackRock	5.75 mm	+5.75 mm	NEW
BLK BlackRock	0.00	-5.59 mm	EXIT
Wellington Management	7.90 mm	+2.78 mm	+54.4%
Point72 Asset Management	1.30 mm	+1.30 mm	NEW
Braidwell	0.00	-1.08 mm	EXIT
Deep Track Capital	689.78 k	+689.78 k	NEW
Yiheng Capital Management	758.77 k	-675.41 k	-47.1%
MS Morgan Stanley	448.07 k	-498.46 k	-52.7%
RTW Investments	5.92 mm	+487.45 k	+9.0%
T. Rowe Price Investment Management	1.30 mm	-467.15 k	-26.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

AKRO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Feb 25	Rolph Timothy	Common Stock	Sell	Dispose S	No	Yes	56.924	5,903	336.02 k	170,237
5 Feb 25	Rolph Timothy	Common Stock	Sell	Dispose S	No	Yes	56.325	12,847	723.61 k	176,140
5 Feb 25	Rolph Timothy	Common Stock	Option exercise	Acquire M	No	Yes	21.1	18,750	395.63 k	188,987
5 Feb 25	Rolph Timothy	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	21.1	18,750	395.63 k	47,468
3 Feb 25	Young Jonathan	Common Stock	Sell	Dispose S	No	Yes	54.057	4,900	264.88 k	251,147
3 Feb 25	Young Jonathan	Common Stock	Sell	Dispose S	No	Yes	53.565	5,100	273.18 k	256,047
30 Jan 25	Graham G. Walmsley	Common Stock	Buy	Acquire P	Yes	No	48	200,000	9.60 mm	1,000,000
27 Jan 25	Cheng Andrew	Common Stock	Sell	Dispose S	No	Yes	56.89	3,377	192.12 k	716,062
27 Jan 25	Cheng Andrew	Common Stock	Sell	Dispose S	No	Yes	55.53	2,381	132.22 k	719,439
27 Jan 25	Cheng Andrew	Common Stock	Sell	Dispose S	No	Yes	54.56	24,242	1.32 mm	721,820

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?

Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners experiencing significant growth due to strategic developments.

UBS Maintains Buy on Akero Therapeutics, Raises Price Target to $109

UBS analyst Eliana Merle maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $42 to $109.

B of A Securities Upgrades Akero Therapeutics to Buy, Raises Price Target to $63

B of A Securities analyst Alexandria Hammond upgrades Akero Therapeutics (NASDAQ:AKRO) from Neutral to Buy and raises the price target from $35 to $63.

Reported Earlier, Akero Therapeutics Prices $350M Upsized Public Offering Of 5,333,420 Common At $48/Share

9 Health Care Stocks With Whale Alerts In Today's Session

Press releases

From Benzinga Pro

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked

Akero Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.